Global Information
회사소개 | 문의

2형 당뇨병 : 파이프라인 리뷰

Type 2 Diabetes - Pipeline Review, H1 2018

리서치사 Global Markets Direct
발행일 2018년 05월 상품 코드 232774
페이지 정보 영문 1109 Pages
가격
US $ 2,500 ₩ 2,805,500 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 5,611,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,500 ₩ 8,416,500 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


2형 당뇨병 : 파이프라인 리뷰 Type 2 Diabetes - Pipeline Review, H1 2018
발행일: 2018년 05월 페이지 정보 : 영문 1109 Pages

한글목차

2형 당뇨병은 만성적인 증상으로, 가장 흔히 볼 수 있는 당뇨병입니다. 혈당치가 높은 것이 특징이며, 인체가 인슐린에 저항하거나 충분한 인슐린을 생성할 수 없게 됩니다. 인슐린 기능 이상에 의해 포도당이 농축되어 혈당이 높아지게 되고, 2형 당뇨병을 일으킵니다. 증후는 피로감, 체중 감소, 눈의 침침함 등 다양한 영향이 생깁니다. 위험요인으로는 가족 병력, 비만, 운동부족, 고혈압 등을 들 수 있습니다. 라이프스타일 재검토와 정기적인 약물치료 등으로 대처합니다.

2형 당뇨병(Type 2 Diabetes) 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업과 연구기관이 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트 관련 정보, 최신 뉴스와 발표 등의 정보를 전해드립니다.

서론

2형 당뇨병 개요

치료제 개발

2형 당뇨병 : 치료제 평가

2형 당뇨병 치료제 개발 참여 기업

약제 개요

휴지 상태의 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

부록

LSH 17.07.24

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

영문목차

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Type 2 Diabetes - Pipeline Review, H1 2018, provides an overview of the Type 2 Diabetes (Metabolic Disorders) pipeline landscape.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Type 2 Diabetes - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Type 2 Diabetes (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Type 2 Diabetes (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type2 diabetes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 10, 2, 29, 63, 72, 6, 220, 65 and 12 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 1, 62 and 18 molecules, respectively.

Type 2 Diabetes (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Type 2 Diabetes (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Type 2 Diabetes (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Type 2 Diabetes (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Type 2 Diabetes (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Type 2 Diabetes (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • Introduction 11
  • Type2 diabetes - Overview 12
  • Type2 diabetes - Therapeutics Development 13
  • Type2 diabetes - Therapeutics Assessment 67
  • Type2 diabetes - Companies Involved in Therapeutics Development 88
  • Type2 diabetes - Drug Profiles 177
  • Type2 diabetes - Dormant Projects 996
  • Type2 diabetes - Discontinued Products 1035
  • Type2 diabetes - Product Development Milestones 1045
  • Appendix 1055

List of Tables

  • Number of Products under Development for Type2 diabetes, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Type2 diabetes - Pipeline by Adocia SAS, H1 2018
  • Type2 diabetes - Pipeline by Aegis Therapeutics LLC, H1 2018
  • Type2 diabetes - Pipeline by AFFiRiS AG, H1 2018
  • Type2 diabetes - Pipeline by Akcea Therapeutics Inc, H1 2018
  • Type2 diabetes - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H1 2018
  • Type2 diabetes - Pipeline by Amarantus Bioscience Holdings Inc, H1 2018
  • Type2 diabetes - Pipeline by Amgen Inc, H1 2018
  • Type2 diabetes - Pipeline by Aphios Corp, H1 2018
  • Type2 diabetes - Pipeline by Arecor Ltd, H1 2018
  • Type2 diabetes - Pipeline by Arena Pharmaceuticals Inc, H1 2018
  • Type2 diabetes - Pipeline by AstraZeneca Plc, H1 2018
  • Type2 diabetes - Pipeline by AusBio Ltd, H1 2018
  • Type2 diabetes - Pipeline by Avadel Pharmaceuticals Plc, H1 2018
  • Type2 diabetes - Pipeline by Bayer AG, H1 2018
  • Type2 diabetes - Pipeline by Betagenon AB, H1 2018
  • Type2 diabetes - Pipeline by Betta Pharmaceuticals Co Ltd, H1 2018
  • Type2 diabetes - Pipeline by Biocon Ltd, H1 2018
  • Type2 diabetes - Pipeline by BioLingus AG, H1 2018
  • Type2 diabetes - Pipeline by BioRestorative Therapies Inc, H1 2018
  • Type2 diabetes - Pipeline by Biozeus, H1 2018
  • Type2 diabetes - Pipeline by Biscayne Pharmaceuticals Inc, H1 2018
  • Type2 diabetes - Pipeline by Boehringer Ingelheim GmbH, H1 2018
  • Type2 diabetes - Pipeline by Boston Therapeutics Inc, H1 2018
  • Type2 diabetes - Pipeline by Braasch Biotech LLC, H1 2018
  • Type2 diabetes - Pipeline by Bristol-Myers Squibb Co, H1 2018
  • Type2 diabetes - Pipeline by C4X Discovery Holdings PLC, H1 2018
  • Type2 diabetes - Pipeline by Cadila Healthcare Ltd, H1 2018
  • Type2 diabetes - Pipeline by Cadila Pharmaceuticals Ltd, H1 2018
  • Type2 diabetes - Pipeline by Caelus Health, H1 2018
  • Type2 diabetes - Pipeline by Cardax Inc, H1 2018
  • Type2 diabetes - Pipeline by Carmot Therapeutics Inc, H1 2018
  • Type2 diabetes - Pipeline by Cellix Bio Pvt Ltd, H1 2018
  • Type2 diabetes - Pipeline by Celon Pharma SA, H1 2018
  • Type2 diabetes - Pipeline by Center Laboratories Inc, H1 2018
  • Type2 diabetes - Pipeline by Chipscreen Biosciences Ltd, H1 2018
  • Type2 diabetes - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018
  • Type2 diabetes - Pipeline by Cinnagen Co, H1 2018
  • Type2 diabetes - Pipeline by CJ HealthCare Corp, H1 2018
  • Type2 diabetes - Pipeline by CohBar Inc, H1 2018
  • Type2 diabetes - Pipeline by Concenter BioPharma Silkim Ltd, H1 2018
  • Type2 diabetes - Pipeline by CymaBay Therapeutics Inc, H1 2018
  • Type2 diabetes - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2018
  • Type2 diabetes - Pipeline by Daiichi Sankyo Co Ltd, H1 2018
  • Type2 diabetes - Pipeline by Dance Biopharm Inc, H1 2018
  • Type2 diabetes - Pipeline by Delpor Inc, H1 2018
  • Type2 diabetes - Pipeline by Diabetology (Products) Ltd, H1 2018
  • Type2 diabetes - Pipeline by Diamyd Medical AB, H1 2018
  • Type2 diabetes - Pipeline by Diasome Pharmaceuticals Inc, H1 2018
  • Type2 diabetes - Pipeline by DiscoveryBiomed Inc, H1 2018
  • Type2 diabetes - Pipeline by DNJ Pharma Inc, H1 2018
  • Type2 diabetes - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2018
  • Type2 diabetes - Pipeline by Elcelyx Therapeutics Inc, H1 2018
  • Type2 diabetes - Pipeline by Eli Lilly and Co, H1 2018
  • Type2 diabetes - Pipeline by Eloxx Pharmaceuticals Inc, H1 2018
  • Type2 diabetes - Pipeline by Energenesis Biomedical Co Ltd, H1 2018
  • Type2 diabetes - Pipeline by Enteris BioPharma Inc, H1 2018
  • Type2 diabetes - Pipeline by Enzene Biosciences Ltd, H1 2018
  • Type2 diabetes - Pipeline by Enzo Biochem Inc, H1 2018
  • Type2 diabetes - Pipeline by Epichem Pty Ltd, H1 2018
  • Type2 diabetes - Pipeline by Eternygen GmbH, H1 2018
  • Type2 diabetes - Pipeline by Evotec AG, H1 2018

List of Figures

  • Number of Products under Development for Type2 diabetes, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Top 10 Targets, H1 2018
  • Number of Products by Stage and Top 10 Targets, H1 2018
  • Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Top 10 Routes of Administration, H1 2018
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2018
  • Number of Products by Top 10 Molecule Types, H1 2018
  • Number of Products by Stage and Top 10 Molecule Types, H1 2018
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
La Merie Publishing
BCC Research